Anal Carcinoma

News alerts, weekly reports and conference planners

No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	MIXE Sensitive: A2 - Guideline MIXE Sensitive : A2	MIXE Sensitive: A2 - Guideline MIXE Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	TPF Sensitive: A2 - Guideline TPF Sensitive : A2	TPF Sensitive: A2 - Guideline TPF Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	FOLFCIS Sensitive: A2 - Guideline FOLFCIS Sensitive : A2	FOLFCIS Sensitive: A2 - Guideline FOLFCIS Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	mFOLFOX6 Sensitive: A2 - Guideline mFOLFOX6 Sensitive : A2	mFOLFOX6 Sensitive: A2 - Guideline mFOLFOX6 Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	DCF Sensitive: A2 - Guideline DCF Sensitive : A2	DCF Sensitive: A2 - Guideline DCF Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + carboplatin Sensitive: A2 - Guideline cisplatin + carboplatin Sensitive : A2	cisplatin + carboplatin Sensitive: A2 - Guideline cisplatin + carboplatin Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + 5-fluorouracil + capecitabine Sensitive: A2 - Guideline cisplatin + 5-fluorouracil + capecitabine Sensitive : A2	cisplatin + 5-fluorouracil + capecitabine Sensitive: A2 - Guideline cisplatin + 5-fluorouracil + capecitabine Sensitive : A2
PD-L1 expression	Anal Carcinoma	PD-L1 expression	Anal Carcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
PD-L1 overexpression + TMB-H	Anal Carcinoma	PD-L1 overexpression + TMB-H	Anal Carcinoma	EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials EGFR inhibitor + Immunotherapy Sensitive : C3	EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials EGFR inhibitor + Immunotherapy Sensitive : C3
CD163 expression	Anal Carcinoma	CD163 expression	Anal Carcinoma	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3
CD4 expression	Anal Carcinoma	CD4 expression	Anal Carcinoma	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3
PD-L1 expression	Anal Carcinoma	PD-L1 expression	Anal Carcinoma	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3
PD-L1 amplification + PD-L2 amplification + TMB-H	Anal Carcinoma	PD-L1 amplification + PD-L2 amplification + TMB-H	Anal Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

Anal Carcinoma

Associations(21)

Associations
(21)